Olon, a top chemical-pharmaceutical group specializing in the production and development of active pharmaceutical ingredients (APIs) and a part of the P&R holding company, is advancing its growth strategy with a new acquisition. The company has announced plans to acquire HuvePharma Italia Srl and its production facility in Garessio, Cuneo, Italy, significantly boosting its overall production capacity.
Olon, a leading chemical-pharmaceutical group specializing in active pharmaceutical ingredients (APIs) and part of the P&R holding company, is advancing its growth strategy with a new acquisition. The company plans to fully integrate Huvepharma Italia Srl and revitalize the Garessio plant’s production capabilities. This acquisition will increase Olon’s manufacturing presence to nine plants in Italy and expand its total reaction capacity to 3,250 cubic meters, establishing it as a major industrial player in both national and European markets in terms of size and production potential.
Huvepharma Italia Srl, which operates the Garessio plant in Cuneo, Piedmont, is involved in the development, industrialization, and production of pharmaceutical active ingredients and advanced intermediates. The plant, previously owned by Sanofi and since 2016 by Huvepharma Italia Srl, has a strong track record in pharmaceutical chemicals and is recognized for its expertise in new technologies. Notably, the Garessio site has developed an important antimalarial product using advanced photo-oxidation technology and produces nanoparticles with half of its production lines fully automated.
Olon’s Expansion Strategy
Since its establishment, Olon has focused on growth, consolidation, and global market expansion through both internal development and acquisitions. The acquisition of Huvepharma Italia aligns with Olon’s strategy to enhance its production capacity and global presence in the API market. The integration will encompass all assets—facilities, workforce, and product portfolio—strengthening and broadening Olon’s product offerings, particularly in key strategic areas.
Paolo Tubertini, CEO of Olon Group, commented, “Huvepharma Italia possesses all the right attributes for our growth strategy. This acquisition is a significant step in advancing our medium to long-term objectives. We will leverage the integration with our existing network of 12 sites worldwide and 7 research centers, our extensive customer portfolio, and our established reputation as a trusted API supplier.”
